H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Bookmakers up and down the country are preparing their odds for the 2025 season - including on who will lift the Championship' Shield.

Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Viking Therapeutics in a research note issued on Thursday, February 6th. HC Wainwright analyst J. Pantginis expects that ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.